Locus co-founders open door to new CRISPR systems

A different type of CRISPR system that works in human cells creates new therapeutic opportunities

As most gene editing companies remain laser-focused on the well-studied CRISPR-Cas9 system marred in IP disputes, a new study from Locus co-founders shows that an entirely different type of CRISPR system can tune gene expression in eukaryotic cells.

The discovery opens the field to a potentially huge collection of new CRISPR systems, some of which could have technical benefits and all of which should have a less complicated patent landscape than their more established Cas9 counterpart.


Read the full 772 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers